HighTower Advisors’s Insys Therapeutics, Inc. INSY Stock Holding History

HighTower Advisors’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-22,378	Closed	-$215K	–	2400
2017 Q4	$215K	Buy	+22,378	New	+$146K	﹤0.01%	1879

Other funds holding INSY

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's INSY Position: Q1 2018 in Review

HighTower Advisors sold out of Insys Therapeutics, Inc. (INSY) in Q1 2018, closing a stake of 22,378 shares — an estimated $215K sold.

HighTower Advisors first reported a position in INSY in Q4 2017 and held it in 1 quarter. The position peaked at $215K in Q4 2017. 110 funds tracked by Wall St. Rank hold INSY as of Q1 2018.

HighTower Advisors reported no remaining Insys Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
HighTower Advisors sold 22,378 Insys Therapeutics, Inc. shares in Q1 2018, an estimated $215K.
HighTower Advisors first reported a position in Insys Therapeutics, Inc. in Q4 2017 and held it in 1 quarter.
HighTower Advisors's Insys Therapeutics, Inc. position peaked at $215K in Q4 2017.
110 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2018.

Based on HighTower Advisors's 13F filing for Q1 2018, filed 15 May 2018.